Cargando…

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors

Modern immunotherapy together with targeted therapy has revolutionized the treatment of advanced melanoma. Inhibition of immune checkpoints significantly improved the median overall survival and gave hope to many melanoma patients. However, this treatment has three serious drawbacks: high cost, seri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olbryt, Magdalena, Rajczykowski, Marcin, Widłak, Wiesława
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313051/ https://www.ncbi.nlm.nih.gov/pubmed/32517213 http://dx.doi.org/10.3390/ijms21114071

Ejemplares similares

NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-Cancer Cell-Free Assay
por: Olbryt, Magdalena, et al.
Publicado: (2021)

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy
por: Olbryt, Magdalena, et al.
Publicado: (2020)

Impact of heat shock transcription factor 1 on global gene expression profiles in cells which induce either cytoprotective or pro-apoptotic response following hyperthermia
por: Kus-Liśkiewicz, Małgorzata, et al.
Publicado: (2013)

Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives
por: Olbryt, Magdalena
Publicado: (2022)

Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019)

Molecular background of skin melanoma development and progression: therapeutic implications
por: Olbryt, Magdalena
Publicado: (2019)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
por: Tomela, Katarzyna, et al.
Publicado: (2020)

Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel
por: Vydra, Natalia, et al.
Publicado: (2013)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

An Increase in HSF1 Expression Directs Human Mammary Epithelial Cells toward a Mesenchymal Phenotype
por: Vydra, Natalia, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Masson, Claire, et al.
Publicado: (2023)

Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota
por: Bouferraa, Youssef, et al.
Publicado: (2023)

Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis
por: Alorfi, Nasser M, et al.
Publicado: (2022)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
por: Marco, Tucci, et al.
Publicado: (2019)

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
por: Vukadin, Sonja, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
por: Simon, Sonja C. S., et al.
Publicado: (2020)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing
por: van Akkooi, Alexander C. J., et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside
por: Solimando, Antonio G., et al.
Publicado: (2020)

Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection
por: Flynn, Michael, et al.
Publicado: (2018)

Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
por: Bianco, Andrea, et al.
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
por: Petrova, Vera, et al.
Publicado: (2020)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Machine Learning Improves the Prediction of Responses to Immune Checkpoint Inhibitors in Metastatic Melanoma
por: Tabari, Azadeh, et al.
Publicado: (2023)

Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review
por: Ouwerkerk, Wouter, et al.
Publicado: (2019)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma
por: Ferraresi, Virginia, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
por: Grywalska, Ewelina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9gnmgnvuhhfknl0i13366qsub5